Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain’s Chicago Business, ranking number two. Crain’s compiles the list based on a review by independent intellectual property valuation firm, Ocean Tomo, which evaluates companies that were awarded at least five patents last year.
Horizon made this year’s list based on its work with its medicine used to treat urea cycle disorders (UCD), a rare genetic disorder that affects approximately 1 in 35,000 live births in the United States.
“At Horizon, we place special emphasis on innovation where we apply scientific expertise to address the most challenging needs patients face,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We are honored to be recognized by Crain’s for our efforts and will continue to move decisively through the clinical process, to bring new and novel therapies to patients, their families and those who care for them.”
About Crain’s Chicago Business
For 40 years, Crain’s Chicago Business has been a top source of news, analysis and information on business in metropolitan Chicago for decision-makers in the private and public sectors. More than a collection of products, Crain’s Chicago Business is a rich media environment—in print, online, mobile, video, live events and executive training.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.